Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2026; 17(2): 113221
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.113221
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.113221
Farrerol and the miR-29b-3p/sirtuin 1 pathway: A mechanistic breakthrough in protecting the diabetic heart
Javier Donate-Correa, Research Unit, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife 38010, Spain
Carlos E Martínez-Alberto, School of Nursing, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife 38010, Spain
Author contributions: Martínez-Alberto CE and Donate-Correa J contributed to the conception, writing, and critical revision of the manuscript. Both authors approved the final version and are accountable for all aspects of the work.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Javier Donate-Correa, PhD, Research Unit, University Hospital Nuestra Señora de Candelaria, Carretera del Rosario S/N, Santa Cruz de Tenerife 38010, Spain.
Received: August 20, 2025
Revised: October 24, 2025
Accepted: December 12, 2025
Published online: February 15, 2026
Processing time: 171 Days and 14.9 Hours
Revised: October 24, 2025
Accepted: December 12, 2025
Published online: February 15, 2026
Processing time: 171 Days and 14.9 Hours
Core Tip
Core Tip: Diabetic cardiomyopathy (DCM) is a diabetes-related form of heart failure that lacks targeted therapies. Recent evidence identifies endothelial ferroptosis, an iron-dependent form of cell death, as a central driver of cardiac microvascular injury in DCM. Guo et al demonstrate that Farrerol, a natural flavonoid, inhibits ferroptosis by downregulating microRNA-29b-3p and restoring sirtuin 1 signaling in endothelial cells, thereby improving cardiac function and reducing fibrosis in diabetic mice. Targeting endothelial ferroptosis through the microRNA-29b-3p/sirtuin 1 pathway represents a novel disease-modifying strategy for DCM.